8 episodes

The European Haematology Association took place June 14 - 17, 2012 in Amsterdam and focuses on drug developments, biomarkers and haematological cancers.

17th European Haematology Association (EHA) Congress ecancer

    • Medicine

The European Haematology Association took place June 14 - 17, 2012 in Amsterdam and focuses on drug developments, biomarkers and haematological cancers.

    • video
    Use of mesenchymal stromal cells against graft-versus-host disease: Prof Willem Fibbe – Lieden University Medical Center

    Use of mesenchymal stromal cells against graft-versus-host disease: Prof Willem Fibbe – Lieden University Medical Center

    Prof Willem Fibbe talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about the use of mesencymal stromal cells and graft-versus-host disease.

    Mesenchymal stromal cells and stem cells have the ability to modulate and suppress immune responses.

    These cells are used to suppress a particular disease, graft-versus-host disease, which comes from an allergic response during the transplantation of cells.

    These cells are harvested from bone marrow and other tissue sources. Normally a specific donor is chosen for each patient.

    Prof Fibbe also discusses a randomised study that will focus on severe graft-versus-host disease, which also affects the liver, where the patient will be treated with steroids and then two infusions of MSCs, one week apart, if there is no response to steroids.

    • 9 min
    • video
    Best treatment for chronic lymphocytic leukaemia with 17p deletion: Prof Michael Keating - MD Anderson Cancer Center, TX

    Best treatment for chronic lymphocytic leukaemia with 17p deletion: Prof Michael Keating - MD Anderson Cancer Center, TX

    Prof Keating talks to ecancer at the 2012 European Haematology Association conference in Amsterdam.

    He covers how to treat chronic lymphocytic leukaemia (CLL), which can be often best left alone. He suggests that the current best treatment is the FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen.

    Another option is the BR (Bendamustine, Rituximab) regimen which has yet to be fully tested. 17p deletion type CLL unfortunately has a much worse outcomes than other CLL types.

    Prof Keating also covers alemtuzumab, allogeneic stem cell transplant and new molecule PCI32765 as an oral medication.

    • 8 min
    • video
    Patient and doctor communication and quality of life guidelines: Jan Geissler – CML Advocates Network

    Patient and doctor communication and quality of life guidelines: Jan Geissler – CML Advocates Network

    Leading patient advocate Jan Gessler talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about patient advocacy in haematologic malignancy treatment.

    Quality of life treatment for patients does not just include day-to-day caring, but the effects on the patient community as a whole.

    A session at EHA 17 showed doctor's and patient's common miscommunications which occur when doctors misinterpret how patients feel either because of due to misunderstandings or lack of information.

    Recently, guidelines on the quality of life care was published for haematologists, setting criteria and providing an example of how doctors should address and assess these issues.

    • 4 min
    • video
    Drug sensitivity and resistance in acute myeloid leukaemia: Dr Mark Frattini – Memorial Sloan-Kettering Cancer Center

    Drug sensitivity and resistance in acute myeloid leukaemia: Dr Mark Frattini – Memorial Sloan-Kettering Cancer Center

    ecancer talks to Dr Mark Frattini, at the 17th European Haematology Association Congress in Amsterdam, about a method of testing patients with acute myeloid leukaemia in order to identify drug sensitivity and resistance.

    The test looks at patient’s cells by placing them in a type of acid for four days, and then checking them with up to 60 agents to identify their response; agents used include novel agents and FDA approved agents. The results from this test build a personal treatment for each patient.

    The study was conducted in a retrospective fashion with 25 patients to show sensitivity and resistance to prior treatments. This did allow for new treatments to be identified for five patients in the study, generating enough response to allow for bone marrow transplants.

    Dr Frattini now hopes to put this test into a prospective setting with a phase 1 clinical trial.

    • 5 min
    • video
    Assessing iron overload and toxicity: Prof John Porter - University College London, UK

    Assessing iron overload and toxicity: Prof John Porter - University College London, UK

    Prof Porter talks to ecancer at the European Haematology Association meeting in Amsterdam June 2012. Iron overload can cause death when patients have survived other diseases such as cancer.

    Progress has been made in to understanding the molecular processes behind haemochromatosis and new MRI techniques allow clear imaging.
    Individuals at the greatest risk of iron overload can now be identified and given personalised treatment accordingly.

    Dr Porter looks at upcoming tools for assessing iron overload and covers iron level issues in myelodysplastic syndrome (MDS).

    • 7 min
    • video
    Signaling and targeting cellular pathways in leukaemia metabolism: Dr Jing Chen – Emory University School of Medicine, Atlant

    Signaling and targeting cellular pathways in leukaemia metabolism: Dr Jing Chen – Emory University School of Medicine, Atlant

    Dr Jing Chen talks to ecancer at the 17th European Haematology Association Congress in Amsterdam about tyrosine phosphorylation and cell metabolism in leukaemia.

    Understanding how cancer changes the cellular metabolism and how leukaemia cells generate ATP energy is still in its early stage, though it is known that tyrosine phosphorylation occurs because of the cancer.

    The most important work done now is to understand how post-translational modification would change properties at the cellular level and the identification and understanding of critical players in cellular pathways, allowing for use as therapeutic targets.

    Dr Chen discusses PK-2, which is the most important enzyme as it controls speed of glycolosis, and LDH, which have already been identified as important therapeutic targets.

    • 8 min

Top Podcasts In Medicine

More by ecancer